CoChat

Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Bipolar I and II represent the most common and severe subtypes of bipolar disorder. Although bipolar I disorder is relatively well studied, the clinical characteristics and response to treatment of patients with bipolar II disorder are less well understood. METHODS: To compare the severity and burden of illness of patients with bipolar II versus bipolar I disorder, baseline demographic, clinical, and quality of life data were examined in 1900 patients with bipolar I and 973 patients with bipolar II depression, who were enrolled in five similarly designed clinical placebo-controlled trials of quetiapine immediate-release and quetiapine extended-release. Acute (8 weeks) response to treatment was also compared by assessing rating scale scores, including Montgomery-Åsberg depression rating scale, Hamilton rating scale for anxiety, Young mania rating scale, and clinical global impression-severity scores, in the bipolar I and II populations in the same pooled database. RESULTS: Patients with bipolar I and bipolar II depression were similar in demographics, baseline rating scale scores (depression, anxiety, mania, and quality of life), and mood episode histories. Symptom improvements in response to quetiapine were greater versus comparators (lithium, paroxetine, and placebo) at 4 and 8 weeks in both bipolar I and II patients. Patients with the bipolar II subtype initially showed slower responses to all treatments, but, by 8 weeks, attained similar symptom improvement as patients with bipolar I depression. CONCLUSIONS: Pooled analysis of five clinical trials of quetiapine demonstrated that patients with bipolar II depression have a similar burden of illness and quality of life to patients with bipolar I. Bipolar II patients consistently showed a slower response to treatments than bipolar I patients, but, after 8 weeks of treatment with quetiapine, symptom improvements were similar between bipolar I and II disorder subtypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12991-016-0096-0

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Designs of the five acute bipolar depression studies of quetiapine IR and XR. aAt least 5 half-lives of any prior psychotropic medications
Fig. 1 Designs of the five acute bipolar depression studies of quetiapine IR and XR. aAt least 5 half-lives of any prior psychotropic medicationsCC BY · PubMed Central
Fig. 2 History of mood episodes in patients in bipolar I or II subgroups (pooled population)
Fig. 2 History of mood episodes in patients in bipolar I or II subgroups (pooled population)CC BY · PubMed Central
Fig. 3 Individual item scores for depression (a) and anxiety (b) at baseline in bipolar I and II subgroups (pooled population). HAM-A Hamilton rating scale for anxiety, MADRS Montgomery–Åsberg depression rating scale. HAM-A was not measured in Suppes et al. [25]. Rating scale ranges: HAM-A: total score range 0–56; MADRS: total score range 0–60. For all rating scales, a high score represents greater severity
Fig. 3 Individual item scores for depression (a) and anxiety (b) at baseline in bipolar I and II subgroups (pooled population). HAM-A Hamilton rating scale for anxiety, MADRS Montgomery–Åsberg depression rating scale. HAM-A was not measured in Suppes et al. [25]. Rating scale ranges: HAM-A: total score range 0–56; MADRS: total score range 0–60. For all rating scales, a high score represents greater severityCC BY · PubMed Central
Fig. 4 Patient-reported functioning and quality of life at baseline in bipolar I and II subgroups (pooled population). Q-LES-Q Quality of Life Enjoyment and Satisfaction Questionnaire, SDS Sheehan Disability Scale. SDS was not measured in Calabrese et al. (2005) or Suppes et al. [25]. Q-LES-Q was not measured in Young et al. [28] or Suppes et al [25]. Rating scale ranges: Q-LES-Q: total score range 14–70; a high score represents greater enjoyment/satisfaction. SDS: total score range 0–30 (individual item score ranges: 0–10); a high score represents greater severity
Fig. 4 Patient-reported functioning and quality of life at baseline in bipolar I and II subgroups (pooled population). Q-LES-Q Quality of Life Enjoyment and Satisfaction Questionnaire, SDS Sheehan Disability Scale. SDS was not measured in Calabrese et al. (2005) or Suppes et al. [25]. Q-LES-Q was not measured in Young et al. [28] or Suppes et al [25]. Rating scale ranges: Q-LES-Q: total score range 14–70; a high score represents greater enjoyment/satisfaction. SDS: total score range 0–30 (individual item score ranges: 0–10); a high score represents greater severityCC BY · PubMed Central
Fig. 5 Least squares mean change from baseline to week 8 in MADRS total score (ITT population, LOCF), BPI and BPII groups. Rating scale range: MADRS: total score range 0–60. A reduction in score represents improvement in depressive symptoms
Fig. 5 Least squares mean change from baseline to week 8 in MADRS total score (ITT population, LOCF), BPI and BPII groups. Rating scale range: MADRS: total score range 0–60. A reduction in score represents improvement in depressive symptomsCC BY · PubMed Central
Fig. 6 Least squares mean change from baseline to week 8 in MADRS individual item scores (ITT population, LOCF), BPI and BPII groups. Rating scale range: MADRS: all item scores range 0–6. A reduction in score represents improvement in depressive symptoms. MADRS items: (1) apparent sadness; (2) reported sadness; (3) inner tension; (4) reduced sleep; (5) reduced appetite; (6) concentration difficulties; (7) lassitude; (8) inability to feel; (9) pessimistic thoughts; (10) suicidal thoughts
Fig. 6 Least squares mean change from baseline to week 8 in MADRS individual item scores (ITT population, LOCF), BPI and BPII groups. Rating scale range: MADRS: all item scores range 0–6. A reduction in score represents improvement in depressive symptoms. MADRS items: (1) apparent sadness; (2) reported sadness; (3) inner tension; (4) reduced sleep; (5) reduced appetite; (6) concentration difficulties; (7) lassitude; (8) inability to feel; (9) pessimistic thoughts; (10) suicidal thoughtsCC BY · PubMed Central
Fig. 7 Least squares mean change from baseline to week 8 in CGI-BP-S score (ITT population, LOCF), BPI and BPII groups. Rating scale range: CGI-S: total score range 0–7. A reduction in score represents improvement in overall severity of symptoms
Fig. 7 Least squares mean change from baseline to week 8 in CGI-BP-S score (ITT population, LOCF), BPI and BPII groups. Rating scale range: CGI-S: total score range 0–7. A reduction in score represents improvement in overall severity of symptomsCC BY · PubMed Central
Fig. 8 Least squares mean change from baseline to week 8 in HAM-A score (ITT population, LOCF), BPI and BPII groups. Rating scale range: HAM-A: total score range 0–56. A reduction in score represents improvement in anxiety symptoms
Fig. 8 Least squares mean change from baseline to week 8 in HAM-A score (ITT population, LOCF), BPI and BPII groups. Rating scale range: HAM-A: total score range 0–56. A reduction in score represents improvement in anxiety symptomsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. Guy W. ECDEU assessment manual for psychopharmacology: publication ADM 76-338. Rockville, MD: US Department of Health, Education and Welfare; 1976.

Cited by

See all 32

Metadata

Authors
Datto, C., Pottorf, W. J., Feeley, L., LaPorte, S., & Liss, C.
Affiliations
AstraZeneca (United States) (US)
Corresponding author
Datto, Catherine
Venue
Annals of General Psychiatry
Published
2016-03-11
Volume
15
Issue
1
Pages
9-9
ISSN
1744-859X (ISSN-L)
OpenAlex
W2295288073
Cited by
32
References
37
Citations by year
2026: 2 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 1 · 2018: 5 · 2017: 2
FWCI
2.37
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Annals of General Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
AstraZeneca Pharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
bipolar II disorder, bipolar I disorder, bipolar depression, quetiapine, acute bipolar depression, treatment response, disease burden, quality of life, lithium, paroxetine, pooled analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. https://app.cochat.ai/papers/10.1186/s12991-016-0096-0
The paper
Datto, C., Pottorf, W. J., Feeley, L., LaPorte, S., & Liss, C. (2016). Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Annals of General Psychiatry. https://doi.org/10.1186/s12991-016-0096-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.